Clinical trials: Heart Transplant Recipients
Ischemic Preconditioning
The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient
In recent years, a large number of studies confirmed the protective effect of ischemic preconditioning on myocardium against ischemia/reperfusion injury, but the clinical data of the effectiveness of ischemic preconditioning in…
- Trial name
- NCT03900390
- Testing
- cross-preconditioning
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mengya Liang
Heart Failure, Transplant; Failure, Heart
Cardiopulmonary Stress Testing (CPET) AlloSure Study
1. Cell-free DNA does not vary significantly as a function of the activity of immunologically quiescent cardiac transplant recipients, despite the metabolic demands of the transplanted organ.
- Trial name
- NCT04656080
- Testing
- CPET exercise testing
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Baylor Research Institute
Heart Transplantation, Perfusion
Heart Transplantation Utilizing NRP DCD
This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD).
- Conditions
- Heart Transplantation, Perfusion, Transplant Recipients
- Trial name
- NCT05243914
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Arizona
Kidney Transplant; Complications
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs).
- Trial name
- NCT06059664
- Testing
- Finerenone Oral Tablet
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Heart Transplantation, Cardiac Allograft Vasculopathy
Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Cardiac allograft vasculopathy (CAV) is the major cause of long-term graft failure in heart transplant recipients. Although several immune-mediated and metabolic risk factors have been implicated in the pathogenesis of CAV, no…
- Conditions
- Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection
- Trial name
- PROTECT (NCT00966836)
- Testing
- Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Heart Transplantation
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
The study is designed to evaluate whether Neoral dose optimization together with a therapeutic drug monitoring of Certican will prevent renal dysfunction as observed in the pivotal cardiac trial while maintaining the efficacy.
- Trial name
- NCT00098007
- Testing
- Everolimus (Certican)
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Allograft Vasculopathy
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
1. Early initiation of sirolimus will prevent or delay the development of intimal thickening and subsequent graft failure. 2. Treatment guided by the development of cardiac allograft vasculopathy (CAV) on intravascular ultrasound…
- Trial name
- STOPCAV (NCT01305395)
- Testing
- Sirolimus
- Where
- United States
- Sponsor
- University of Minnesota
Heart Cancer, Kidney Cancer
Cancer Development In Organ Transplant Recipients
The investigators will determine the cancer risk in organ transplant recipients compared to the general population with the help of statistical analysis.
- Conditions
- Heart Cancer, Kidney Cancer, Lung Cancer, Pancreas Cancer
- Trial name
- NCT02333279
- Where
- Switzerland
- Volunteers
- 1,800 people
- Sponsor
- University of Zurich
Cardiac Allograft Vasculopathy
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
The purpose of this study is to test the hypothesis that administering Thymoglobulin® induction therapy early after transplant prevents the development of cardiac allograft vasculopathy (CAV).
- Trial name
- NCT01157949
- Testing
- Thymoglobulin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Cytomegalovirus Infection
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver.
- Trial name
- NCT00817908
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- University of Alberta
Cardiac Allograft Vasculopathy
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and mortality in heart transplant recipients as the second most frequent cause of all deaths at 3 years.
- Trial name
- ACAV (NCT04193306)
- Testing
- Alirocumab
- Where
- Czechia
- Volunteers
- 126 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Heart Transplantation, Exercise Capacity
Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients
The purpose of this study is to investigate the effect of physical training on work capacity and vascular function after heart transplantation, cardiac transplant recipients are randomized to 8 weeks of intense physical training…
- Conditions
- Heart Transplantation, Exercise Capacity, Endothelial Function
- Trial name
- NCT01028599
- Testing
- Intensive physical exercise
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cytomegalovirus Infections, Heart Transplantation
Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use.
- Conditions
- Cytomegalovirus Infections, Heart Transplantation, Kidney Transplantation, Lung Transplantation
- Trial name
- QUANTIFOT (NCT06341543)
- Testing
- Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes)., Communication of the result of the QF-CMV to the clinician in charge
- Where
- France
- Volunteers
- 288 people
- Sponsor
- University Hospital, Grenoble
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Disorder Related to Renal Transplantation
The Effects of Omega-3 Fatty Acids in Renal Transplantation
Omega-3 fatty acids are provided through dietary intake of fish and seafood. Several dietary supplements containing omega-3 fatty acids are also commercially available.
- Trial name
- ORENTRA (NCT01744067)
- Testing
- Omega-3 fatty acids
- Where
- 2 sites in Norway
- Volunteers
- 132 people
- Sponsor
- Oslo University Hospital
Dysphagia, Heart Transplant Recipients
Respiratory Strength Training in Heart Transplant Recipients
This research study is investigating whether completing breathing exercises before surgery helps heart transplant patients recover after surgery.
- Trial name
- NCT06190171
- Testing
- Active respiratory muscle strength training
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vanderbilt University Medical Center
Heart Transplant Recipients
High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients.
The aim of this study was to examine the effects of high intensity aerobic interval training (AIT) versus moderate continuous training (CON) in heart transplant recipients.
- Trial name
- NCT01914406
- Testing
- high intense interval training, continuous moderate training
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Bispebjerg Hospital
Heart Transplant
Impact of mHealth in Heart Transplant Management
The purpose of this study is to improve medication adherence, engagement and support to heart transplant patients through implementation of a new clinical care programme conducted by the clinical pharmacy service in cooperation…
- Trial name
- mHeart (NCT02554578)
- Testing
- Multidisciplinary follow-up programme supported by mHealth
- Volunteers
- 158 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Renal Transplant Recipients
Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation
Introduction: Renal transplantation represents the therapeutic mode with more durable treatment, greater cost-effectiveness, survival benefits and quality of life of the patients, however, with high cardiovascular mortality.
- Trial name
- NCT03110406
- Testing
- whole-body vibration training
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Universidade Federal de Pernambuco
Kidney Transplant
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment…
- Trial name
- NCT03644485
- Testing
- Tacrolimus immediate-release formulation, Tacrolimus prolonged-release formulation, Induction therapy
- Where
- 14 sites in China
- Volunteers
- 284 people
- Sponsor
- Astellas Pharma China, Inc.